GW Pharmaceuticals Plc (GWPH) Social Stream



GW Pharmaceuticals Plc (GWPH): $218.96

0.32 (-0.15%)

POWR Rating

Component Grades

Momentum

N

Stability

N

Sentiment

Quality

N

Add GWPH to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals

Industry

F

Ranked


in industry

Gw Pharmaceuticals Plc (GWPH) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering GWPH.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
16 $270 $126 $184 $218.96 -15.97%

GWPH reports an average of 67.66% for its upside potential over the past 159 days.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2020-11-03 16 270 126 184.00 108.21 70.04%
2020-10-21 16 275 136 190.38 96.89 96.49%
2020-09-26 16 275 136 190.69 100.44 89.85%
2020-09-12 16 275 136 190.69 102.31 86.38%
2020-08-07 16 275 136 190.69 109.37 74.35%
2020-07-14 16 275 140 190.19 139.54 36.3%
2020-06-30 16 275 150 190.56 122.72 55.28%
2020-06-22 16 260 150 188.62 125.85 49.88%
2020-05-28 16 260 150 188.62 125.46 50.34%

GWPH Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • Gw Pharmaceuticals Plc's upside potential (average analyst target price relative to current price) is higher than 2.92% of Pharmaceutical Products stocks.
  • The average analyst price target of GWPH is greater than 96.65% of Pharmaceutical Products stocks.
  • GWPH has a higher number of analysts covering the stock than 95.22% of stocks in the mid market cap category.
  • GWPH has a lower variance in analysts' estimates than 9.56% of all US stocks.

What is the outlook for GWPH? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!